Completed PHASE1 INTERVENTIONAL 1-arm NCT00003207

Liposomal Doxorubicin and PSC 833 in Treating Patients With AIDS-Related Kaposi's Sarcoma or Other Advanced Cancers

Phase I Study on Doxil and SDZ PSC 833 in the Treatment of AIDS-Associated Kaposi's Sarcoma and Other Advanced Malignancies

Sponsor: National Cancer Institute (NCI)

Conditions Sarcoma Unspecified Adult Solid Tumor, Protocol Specific

Interventions PSC 833 pegylated liposomal doxorubicin hydrochloride

Updated 7 times since 2017 Last updated: Apr 11, 2013 Started: Mar 31, 1998 Primary completion: Jul 31, 2002 Completion: Jul 31, 2002

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Sarcoma and Unspecified Adult Solid Tumor, Protocol Specific and is currently completed. National Cancer Institute (NCI) leads this study, which shows 7 recorded versions since 1998 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Mar 1998

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)
Washington University School of Medicine

Data source: Washington University School of Medicine

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• St Louis, United States